1% tenofovir gel

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), CONRAD, Centre for the AIDS Programme of Research in South Africa

Conditions

HIVHIV InfectionsHepatitis B, ChronicPharmacodynamics of 1% Tenofovir Gel Following CoitusPharmacokinetics of 1% Tenofovir Gel Following Coitus

Phase 1

Coital Pharmacokinetics/Pharmacodynamics (PK/PD) of Tenofovir Gel

CompletedNCT01687205

CONRADPharmacodynamics of 1% Tenofovir Gel Following Coitus, Pharmacokinetics of 1% Tenofovir Gel Following Coitus

Start: 2012-11-30End: 2014-11-30Updated: 2021-06-28

Phase 2

Safety and Acceptability of a Vaginal Microbicide

CompletedNCT00111943

National Institute of Allergy and Infectious Diseases (NIAID)Hepatitis B, Chronic, HIV Infections

End: 2007-10-31Updated: 2021-11-01

Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women

WithdrawnNCT01490671

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Updated: 2021-11-01

Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services

CompletedNCT01691768

Centre for the AIDS Programme of Research in South AfricaHIV

Start: 2012-10-31End: 2015-12-31Updated: 2019-11-26

Related Papers

Undue inducement: a case study in CAPRISA 008

Journal of Medical Ethics2017-03-2712 citations

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.

2014-12-198 citations